TNFRSF10B and neoplasm: Tigatuzumab has demonstrated potent in vitro cytotoxic activity against multiple DR5-positive human tumor cell lines, including pancreatic cell lines, and significant in vivo antitumor activity against human tumor xenografts in nude mice with minimal toxicity toward normal tissues [23, 25, 26].